TY - JOUR
T1 - Drug absorption from oral formulations in patients with short bowel syndrome
T2 - a comprehensive update of the literature
AU - Azuz, Samuel
AU - Poulsen, Jakob Lykke
AU - Vinter-Jensen, Lars
AU - Olesen, Anne Estrup
PY - 2023/9
Y1 - 2023/9
N2 - INTRODUCTION: Drug absorption is often altered and typically diminished in patients with short bowel syndrome (SBS). It is important to understand the patient's gastrointestinal anatomy, the absorptive capacity of the remaining bowel, and the physicochemical and pharmacokinetic properties of the drug to optimize oral pharmacotherapy.AREAS COVERED: The primary focus was to provide an updated understanding of the absorption of various drugs in patients with short bowel syndrome. Forty-seven studies covering 13 different drug classes were included in the review and study details, patient characteristics, drug characteristics and pharmacokinetic findings were summarized for each drug class.EXPERT OPINION: Improving and simplifying drug treatment in patients with SBS have high priority, but the patients are multi diseased so knowledge regarding absorption of drugs as e.g. antithrombotic agents, immunosuppressants is urgently needed. Therefore, it is crucial to advance our understanding of the fundamental factors involved in drug absorption, spanning from drug design to pathophysiology. With the growing knowledge in drug design and gastrointestinal pathophysiology, we anticipate the development of computer models that can accurately predict optimal absorption in the future.
AB - INTRODUCTION: Drug absorption is often altered and typically diminished in patients with short bowel syndrome (SBS). It is important to understand the patient's gastrointestinal anatomy, the absorptive capacity of the remaining bowel, and the physicochemical and pharmacokinetic properties of the drug to optimize oral pharmacotherapy.AREAS COVERED: The primary focus was to provide an updated understanding of the absorption of various drugs in patients with short bowel syndrome. Forty-seven studies covering 13 different drug classes were included in the review and study details, patient characteristics, drug characteristics and pharmacokinetic findings were summarized for each drug class.EXPERT OPINION: Improving and simplifying drug treatment in patients with SBS have high priority, but the patients are multi diseased so knowledge regarding absorption of drugs as e.g. antithrombotic agents, immunosuppressants is urgently needed. Therefore, it is crucial to advance our understanding of the fundamental factors involved in drug absorption, spanning from drug design to pathophysiology. With the growing knowledge in drug design and gastrointestinal pathophysiology, we anticipate the development of computer models that can accurately predict optimal absorption in the future.
KW - Bioavailability
KW - drug absorption
KW - intestinal failure
KW - pharmacokinetic
KW - short bowel syndrome
UR - http://www.scopus.com/inward/record.url?scp=85170533376&partnerID=8YFLogxK
U2 - 10.1080/17425255.2023.2256216
DO - 10.1080/17425255.2023.2256216
M3 - Review article
C2 - 37668362
SN - 1742-5255
VL - 19
SP - 577
EP - 600
JO - Expert Opinion on Drug Metabolism & Toxicology
JF - Expert Opinion on Drug Metabolism & Toxicology
IS - 9
ER -